Abbott smartens up its smartphone-based ICM with more accurate detection

The loop recorder connects directly to the user's smartphone via Bluetooth. (Image: Abbott)

Abbott has launched a new, smarter version of its small implantable monitor for detecting irregular heartbeats that the company says now reduces the rate of false detection by 97%.

About the size of a paperclip, the Confirm Rx insertable cardiac monitor connects directly to a smartphone app via Bluetooth, to offer continuous remote detection of arrhythmias without the need for additional transmitter hardware.

The loop recording device, which has been cleared by the FDA and received a CE mark, is placed just under the skin above the heart during an outpatient procedure. Additionally, Abbott’s mobile app is available in nearly 40 languages.


De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

RELATED: Abbott rolls out smartphone-connected ICM in the U.S.

Abbott first picked up the Confirm Rx monitor and its smartphone app through its $25 billion acquisition of St. Jude Medical in January 2017. The device made its international commercial debuts later that year, including in Europe and the U.S.

The tracker is aimed at the estimated 33 million people living with the most common irregular heartbeat, atrial fibrillation, with many going undiagnosed.

RELATED: The top 10 medtech companies of 2024 | Abbott Laboratories

It’s also designed for people with active lifestyles, and offers 24/7 monitoring compared to devices that need to be removed and placed in a charging station, which can lead to gaps in the detection of sporadic and infrequent arrhythmias.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

The supermarket chain received an emergency authorization for its own home collection kit for COVID-19 testing, which includes a telehealth consult.

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.